Debra Patt, MD, PhD, MBA, on the promising investigations of CDK4/6 inhibitors

Debra Patt, MD, PhD, MBA, on the promising investigations of CDK4/6 inhibitors

00:54 |

Related Videos

Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

0:46

Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

Charles Loprinzi, MD, explains the role of palliative and supportive care in medical oncology

2:41

Charles Loprinzi, MD, explains the role of palliative and supportive care in medical oncology

Next-Gen Sequencing is Transforming Oncology Practices

4:27

Next-Gen Sequencing is Transforming Oncology Practices

William K. Oh, MD, considers the role of PARP inhibitors in mCRPC

2:37

William K. Oh, MD, considers the role of PARP inhibitors in mCRPC

Edward Kim, MD, describes how immunotherapy combinations will be used in the near future

1:36

Edward Kim, MD, describes how immunotherapy combinations will be used in the near future

Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists

2:19

Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists

Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

0:58

Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

Debu Tripathy, MD, on the use of hormonal therapy in the PALOMA-2 clinical study

0:41

Debu Tripathy, MD, on the use of hormonal therapy in the PALOMA-2 clinical study

Daniel M. Geynisman, MD, on how real-world analysis influences clinical decision-making

2:20

Daniel M. Geynisman, MD, on how real-world analysis influences clinical decision-making

Alexander Spira, MD, PhD, FACP, on managing lung cancer patients in a community setting

0:50

Alexander Spira, MD, PhD, FACP, on managing lung cancer patients in a community setting

Debra Patt, MD, PhD, MBA, on the promising investigations of CDK4/6 inhibitors

0:54

Debra Patt, MD, PhD, MBA, on the promising investigations of CDK4/6 inhibitors

Jeff Vacirca, MD, explains why OneOncology is a unique practice model

0:52

Jeff Vacirca, MD, explains why OneOncology is a unique practice model

Bo Gamble, compares and contrasts the definition of value and quality as it relates to cancer care

1:59

Bo Gamble, compares and contrasts the definition of value and quality as it relates to cancer care

Will NGS-Based Cancer Tests Become Routine?

3:23

Will NGS-Based Cancer Tests Become Routine?

Christopher J. Kane MD, FACS, on trends in the multimodality treatment of localized prostate cancer

2:55

Christopher J. Kane MD, FACS, on trends in the multimodality treatment of localized prostate cancer

Russell Gollard, MD, explains how IDNs effectively coordinate cancer care

1:44

Russell Gollard, MD, explains how IDNs effectively coordinate cancer care

The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD

0:37

The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD

Erika Hamilton, MD, on how CDK4/6 inhibitors transformed the management of metastatic breast cancer

1:12

Erika Hamilton, MD, on how CDK4/6 inhibitors transformed the management of metastatic breast cancer

Dana Chase, MD, shares details about PRIMA and PAOLA clinical studies regarding ovarian cancer

5:14

Dana Chase, MD, shares details about PRIMA and PAOLA clinical studies regarding ovarian cancer

Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

0:19

Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields